SGLT2 Inhibitors: 5 True or False Questions

The sodium glucose cotransporter-2 inhibitor class of antihyperglycemic agents are proven both safe and effective in treating type 2 diabetes. What do you know about details of registration trials and post-marketing research on the "gliflozins?"Use this first installment of 5 True/False statements above to test your recall and retention.Links for additional information provided below and in slide captions.  References1. FDA approves SGLT2 inhibitor STEGLATRO™ (ertugliflozin) and fixed-dose combination STEGLUJAN™ (ertugliflozin and sitagliptin) for adults with type 2 diabetes [press release]. New York: Pfizer Inc; December 22, 2017.  Accessed January 22 2018. :2. Pinto LC, Rados DV, Remonti LR, et al. Efficacy of SGLT2 inhibitors in glycemic control, weight loss and blood pressure reduction: a systematic review and meta-analysis. Diabetol Metab Syndr. 2015;7: A58. Published online November 11, 2015. doi:  10.1186/1758-5996-7-S1-A58.3. Zinman B, Wanner C ,Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.4. Zhang XL, Zhu QQ, Yu-Han C, et al. Cardiovascular safety, long-term noncardiovascular safety, and efficacy of sodium glucose cotransporter 2 inhibitors in patients with type 2 diabetes mellitus: a systematic review and meta-analysis with trial sequential analysis.  J Am Heart Assoc. 2018;7:e007165. DOI: 10.1161/JAHA.117.0071655. FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) [FDA Drug Safety Communication]. May 16 2017.  Accessed January 22, 2018.